Latest news and research on all cancers and treatments, updated several times a week, plus 10,000-item data base of these
A new type of drug that launches the body's own immune system to fight tumors not only helps defeat melanoma, but lung cancer, too, researchers say ...
Drug Harnesses the Immune System to Fight Lung Cancer - Market Journals
Since than many millions of dollars have been spent in trying to find the links between cancer and the immune system. It's been known for some years ...
She is the first New Mexican to join a clinical trial that will teach her immune system to fight her cancer cells everywhere. The UNM Cancer Center is ...
A protein which "turbo-charges" the immune system, enabling it to fight off any cancer or virus, has been discovered by scientists. Described as a ...
But new research suggests soy may actually be beneficial for cancer survivors, boosting the cancer-fighting immune system and diminishing the ...
Soy-Containing Food Can Prevent Breast Cancer Contrary To Popular Practice, A New Study ... - International Business Times AU
Soy Food Consumption Reduces Recurrence Of Breast Cancer - Science World Report
Fasting Overnight Can Reduce Women's Glucose Levels And Lower Her Risk For Breast Cancer - Medical Daily
PHILADELPHIA — The high hopes for cancer immunotherapy have panned out in metastatic triple-negative breast cancer, a subtype that is ...
| Cancer Network |
... published in the New England Journal of Medicine and presented at the 2015 American Association for Cancer Research (AACR) Annual Meeting.
Research Proves Combination Immunotherapy Significantly More Effective than Ipilimumab Alone ... - Memorial Sloan Kettering Cancer Center (press release)
Chimeric antigen receptor-modified T cells (CART)-meso, a type of investigational adoptive immunotherapy, were well tolerated, persisted in the blood ...
A comprehensive and extended review on last decade's research devoted to cancer, immunity, and immunotherapy has recently been highlighted in a ...
The median time it took for Yervoy patients to see their cancer worsen was 4.4 months. But after 11 months, more than half of the combination group ...
Bristol-Myers: 2 immunotherapy drugs up survival over 1 in melanoma, but worsen side effects - Fox Business
Drug Harnesses Immune System to Fight Lung Cancer - NBCNews.com
Bristol-Myers combination melanoma treatment shows promise - Financial Times
The PD-1 inhibitor pembrolizumab, a cancer immunotherapy drug, shrank or halted growth of tumors in 76 percent of patients with pleural ...
Juno develops immunotherapy treatments for cancer. Its drug candidates for blood cancer have had high success rates in small clinical trials. One of ...
Once again, researchers at Penn's Abramson Cancer Center have extended the reach of the immune system in the fight against metastatic melanoma, ...
Task force stands firm on its controversial call for biennial screening mammography beginning at age 50.Read more
In a study of 30,183 men in the Health Professionals Follow-up Study (HPFS), men with severe LUTS had a 64% higher relative risk of bladder cancer ...
VARANASI: Despite several anti-tobacco campaigns and pictorial warnings on cigarette and tobacco packets, oral cavity cancer cases are on rise ...
The study shows these TERT alterations frequently co-occur with alterations in recently identified bladder cancer genes such as the stromal antigen 2 ...
Anti-PDL1 was designated as Breakthrough Therapy by US Food and Drug Administration (FDA) for bladder cancer in May 2014 and lung cancer in ...
... Sloan Kettering where sequencing identified the reason why a patient with metastaticbladder cancer had a dramatic response to an mTOR inhibitor.
... treated across multiple tumor types, including NSCLC, breast cancer, gastric cancer, ovarian cancer, bladder cancer, melanoma and mesothelioma.
"And it is not just melanoma, with good data emerging in lung cancer, bladder cancer, head and neck cancer showing some promise," Prof McArthur ...
Ottawa researchers have unlocked a way to make pancreatic cancer cells more vulnerable to cancer-killing viruses, known as oncolytic viruses.
Pancreatic cancer cells turned back into normal cells in research breakthrough - International Business Times
PDAC is a type of pancreatic cancer that is typically characterized by a fibro-inflammatory reaction, which makes PDAC a difficult disease to treat with ...
Ibrutinib (IMBRUVICA) may be effective for pancreatic ductal adenocarcinoma - News-Medical.net
Australian leaders of an ongoing pancreatic cancer clinical trial known as the Individualised Molecular Pancreatic Cancer Therapy or 'IMPaCT' trial, ...
Failed Australian pancreatic cancer trial draws international interest - The Australian Financial Review
Real-world targeted treatment based on whole genome sequencing difficult in pancreatic cancer - Medical Xpress
"Despite recent advancements in treating pancreatic cancer, tumors undermine inflammatory and effector immune responses through suppressor cells ...
Doctors at Memorial Sloan Kettering Cancer Center offered her an .... cancer, two with epithelial mesothelioma, and one with pancreatic cancer.
Personalized pancreatic cancer therapies based on tumor genomics may take too long to prepare to be helpful, according to a small clinical trial.
The Challenges of Precision
Researchers face roadblocks to treating an individual patient’s cancer as a unique disease.
Science Daily Cancer News
Long non-coding RNAs (lncRNA) are unusual in that they don’t encode proteins like normal RNA. Yet they do play a role in regulating cellular functions and interest cancer researchers.
Successful ovarian cancer treatment often relies on catching it early. A study may help point to a new method for women at risk.
New findings about regulation of PD-L1, a protein that allows cancer to evade the immune system, has shown therapeutic promise for several cancers, including the most common form of lung cancer.
While dietary supplements may be advertised to promote health, new research shows a link between consumption of over-the-counter supplements and increased cancer risk, if the supplements are taken in excess of the recommended dietary amount.
New findings hidden within the complex machinery behind the chronic inflammation-cancer feedback loop have been discerned.
A new study shows that orally administering the chemical silibinin, purified from milk thistle, slows the ability of colorectal cancer stem cells to grow the disease. When stem cells from tumors grown in silibinin-fed conditions were re-injected into new models, the cells failed to develop equally aggressive tumors even in the absence of silibinin.
Genomic studies have illuminated the ways in which malfunctioning genes can drive cancer growth while stunting the therapeutic effects of chemotherapy and other treatments. But new findings indicate that these genes are only partly to blame for why treatment that was at one point effective ultimately fails for about 40 percent of patients diagnosed with the most common form of non-Hodgkin's lymphoma.
A new combination of drugs has been developed that may overcome treatment resistance and relapse in breast cancer. While most women initially respond well to hormonal treatment with drugs such as tamoxifen, many go on to develop resistance and relapse. There is evidence that this is often due to activation of the Wnt signalling pathway, a gene involved in development which fuels the growth of the tumor.
Patients who are obese, diabetic or both have the highest incidence of brain tumors, and they offer a clue that insulin is a factor for some glioblastoma patients. But a new study suggests drugs tested on such tumors targeted the wrong molecules.
Researchers have unlocked a way to make pancreatic cancer cells more vulnerable to cancer-killing viruses, known as oncolytic viruses. The scientists have discovered how they can exploit the communication, or cross-talk, between pancreatic cancer and a specific cell type that supports the tumor. They found that this cross-talk weakens the ability of both cell types to fight off cancer-fighting viruses.
Researchers have discovered a way to easily and effectively fasten proteins to nanoparticles -- essentially an arranged marriage -- by simply mixing them together. The biotechnology is in its infancy. But it already has shown promise for developing an HIV vaccine and as a way to target cancer cells.
Scientists have found a novel avenue for therapeutic intervention of the "silent cancer." A new research study has shown that pancreatic cancer cells can be coaxed to revert back toward normal cells by introducing a protein called E47. E47 binds to specific DNA sequences and controls genes involved in growth and differentiation. The research provides hope for a new treatment approach for the more than 40,000 people who die from the disease each year in the United States.
Despite strong evidence and guidelines supporting its use, post-surgical radiation therapy for prostate cancer patients at risk of recurrence is declining in the United States. This study finds fewer than 10 percent of patients at risk of recurrence received postoperative radiotherapy within six months of surgery in the U.S.
Adjuvant Ipilimumab significantly improves recurrence-free survival in patients with completely resected stage III melanoma at high risk of disease recurrence, research indicates, but that this treatment was also associated with a high rate of immune-related adverse events.
Higher-than-expected rates of pediatric cancers have been identified in the Miami metro area and an area west of the Everglades in a series of five statistical analyses. Comparisons across analyses reveal characteristics of the detected patterns, including the number of cases (two), types of cancer (leukemia or brain/central nervous system cancer) and the racial composition and timing of the cluster west of the Everglades.
Leaders of an ongoing pancreatic cancer clinical trial known as the Individualized Molecular Pancreatic Cancer Therapy or 'IMPaCT' trial, have been learning ways to bring about about a new paradigm of personalized cancer care for pancreatic cancer and other aggressive cancer types.
Early data in a preliminary human study show that an experimental immune system drug is generally safe and well tolerated in women with metastatic, triple-negative breast cancer, a persistently difficult form of the disease to treat.
Tumor genome sequencing shows the most frequently altered gene in bladder cancer: Telomerase reverse transcriptase
Researchers have reported that the telomerase reverse transcriptase gene promoter was altered in 69 percent of 54 cases of bladder cancer. Telomerase reverse transcriptase alterations frequently co-occur with alterations in recently identified bladder cancer genes such as STAG2 and KDM6A.
A protein produced by nerve cells appears to be elevated in the blood of those with an aggressive form of neuroblastoma. The finding could potentially lead to a prognostic test for the disease or be used to monitor its progress.
Detecting lung cancer at an early stage: 'Spectral histopathology' facilitates prognosis regarding tumour aggressiveness
A new diagnostic method, namely spectral histopathology, facilitates marker-free detection of individual subtypes of lung cancers. It is an automatable imaging process which, by classifying specific forms of lung cancer, facilitates a prognosis regarding a tumor's aggressiveness. The team compares the results of traditional diagnostic procedures with those of spectral histopathology in a new article.
Myc cancer gene makes cells to commit suicide by repressing life supporting "well-being" genes, a new study suggests. These findings provide new opportunities to develop drugs, which could switch Myc from a cancer driver gene to a deadly assassin of the cancer cells, and encourages a rethinking of how to unmask cancer vulnerabilities, scientists say
A research center has enrolled its first patient in a phase 3 clinical trial that uses a person’s own kidney cancer cells to make a vaccine tailored to kill those cells.
The pain Anne Holmes felt in her arm was actually kidney cancer that had spread. She joined a phase 3 clinical trial. The trial tests a new approach that strips the invisibility cloak from spreading kidney cancer cells; it will use Holmes' own cells to create a vaccine tailored for her cancer cells.
A decrease in the amount of time spent eating and an increase in overnight fasting reduces glucose levels and may reduce the risk of breast cancer among women, report researchers. Women who fasted for longer periods of time overnight had significantly better control over blood glucose concentrations. The data shows that each three hour increase in nighttime fasting was associated with a 4 percent lower postprandial glucose level, regardless of how much women ate.
Tambahkan Komentar